Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Acquired by Naviter Wealth LLC

Naviter Wealth LLC increased its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 8.0% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 85,475 shares of the company’s stock after purchasing an additional 6,319 shares during the period. Naviter Wealth LLC’s holdings in Takeda Pharmaceutical were worth $1,215,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Rise Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical during the first quarter valued at approximately $26,000. GAMMA Investing LLC lifted its holdings in Takeda Pharmaceutical by 50.9% in the 1st quarter. GAMMA Investing LLC now owns 2,864 shares of the company’s stock worth $40,000 after buying an additional 966 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Takeda Pharmaceutical by 38.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock valued at $43,000 after buying an additional 859 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Takeda Pharmaceutical during the second quarter valued at about $59,000. Finally, Hexagon Capital Partners LLC increased its position in shares of Takeda Pharmaceutical by 34.3% during the third quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock worth $63,000 after acquiring an additional 1,129 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 1.3 %

NYSE:TAK opened at $14.26 on Friday. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.08. The business’s 50-day simple moving average is $14.60 and its 200 day simple moving average is $13.76. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 1.26. The stock has a market cap of $45.13 billion, a price-to-earnings ratio of 25.93, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Wednesday, July 31st. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.37 by $0.19. The company had revenue of $7.75 billion during the quarter. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. As a group, sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.58 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.